Author

Irit Avni-Biron

PERI-PARTUM INFECTIONS AMONG WOMEN WITH INFLAMMATORY BOWEL DISEASE
PERI-PARTUM INFECTIONS AMONG WOMEN WITH INFLAMMATORY BOWEL DISEASE

Monitoring ulcerative colitis
Monitoring ulcerative colitis

Irit Avni-Biron

Transmural healing in small intestinal Crohn's disease
Transmural healing in small intestinal Crohn's disease

Irit Avni-Biron

RESPONSIVENESS OF FECAL CALPROTECTIN AND QUALITY OF LIFE QUESTIONNAIRES TO CHANGE IN POUCH DISEASE ACTIVITY. RESULTS FROM A PROSPECTIVE TRIAL
RESPONSIVENESS OF FECAL CALPROTECTIN AND QUALITY OF LIFE QUESTIONNAIRES TO CHANGE IN POUCH DISEASE ACTIVITY. RESULTS FROM A PROSPECTIVE TRIAL

Irit Avni-Biron  et al.

European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease
European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease

Irit Avni-Biron  et al.

RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPY FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONG PATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATA FROM A PROSPECTIVE COHORT
RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPY FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONG PATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATA FROM A PROSPECTIVE COHORT

Irit Avni-Biron  et al.

A SIMPLE WEB-BASED TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS USING EXPLAINABLE ARTIFICIAL INTELLIGENCE
A SIMPLE WEB-BASED TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS USING EXPLAINABLE ARTIFICIAL INTELLIGENCE

Irit Avni-Biron  et al.

DECREASED IMMUNE RESPONSE TO COVID-19 MRNA VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI TNF?: A PROSPECTIVE, CONTROLLED, MULTI-CENTER ISRAELI STUDY
DECREASED IMMUNE RESPONSE TO COVID-19 MRNA VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI TNF?: A PROSPECTIVE, CONTROLLED, MULTI-CENTER ISRAELI STUDY

Irit Avni-Biron  et al.

SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Irit Avni-Biron  et al.

MICROBIAL SIGNATURE OF PATIENTS WITH NEWLY DIAGNOSED CROHN’S DISEASE IDENTIFIES PATIENTS WITH COMPLICATED DISEASE COURSE
MICROBIAL SIGNATURE OF PATIENTS WITH NEWLY DIAGNOSED CROHN’S DISEASE IDENTIFIES PATIENTS WITH COMPLICATED DISEASE COURSE

Irit Avni-Biron  et al.

PERI-PARTUM INFECTIONS AMONG WOMEN WITH INFLAMMATORY BOWEL DISEASE
PERI-PARTUM INFECTIONS AMONG WOMEN WITH INFLAMMATORY BOWEL DISEASE

Irit Avni-Biron  et al.

EXTERNAL VALIDATION OF A NOVEL EXPLAINABLE AI-DERIVED WEB TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS
EXTERNAL VALIDATION OF A NOVEL EXPLAINABLE AI-DERIVED WEB TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS

Irit Avni-Biron  et al.

FAVOURABLE FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT
FAVOURABLE FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT

Irit Avni-Biron  et al.

Item 1 - 13 / 13
1